Home Search
companion diagnostics. - search results
If you're not happy with the results, please do another search
Amgen Taps Guardant, Qiagen for AMG 510 NSCLC Companion Dx Partnerships
The deals with each partner will initially focus on the KRAS G12C mutation as found in non-small cell lung cancer (NSCLC), which accounts for approximately 13% of all NSCLC cases.
Takeda, Prometheus Enter IBD Drug-Companion Diagnostic Partnership
Prometheus Biosciences said its bioinformatics platform and advanced machine learning techniques will be used by Takeda Pharmaceutical as part of a global collaboration to...
8 Companion Diagnostic Developers Making a Mark
If companion diagnostics (CDx) were people, they would be old enough to drink. The first CDx won FDA approval in 1998, when Dako Denmark...
FoundationOne CDx Approved as Companion Diagnostic to Lynparza in Ovarian Cancer
The FDA has approved an expanded indication for Foundation Medicine’s FoundationOne®CDx, authorizing the test as a companion diagnostic for the AstraZeneca/Merck & Co. co-developed...
Leveraging I-O Biomarkers for Companion Diagnostic Development
With I-O continuing as the hot area of cancer drug development, new classes of biomarkers have emerged for potential companion diagnostics
Companion Diagnostics Q&A: Dan Snyder, Molecular MD
Dan Snyder, CEO of Molecular MD discusses the new era of companion diagnostics from new technologies to emerging biomarkers.
FDA Approves First NGS Companion Diagnostic that Screens for Multiple Drugs
The approval opens the door for NGS-approved companion diagnostics and for companion diagnostics to move beyond one test for one drug
HTG Expands Collaboration with Merck KGaA Beyond CDx
HTG's year-old collaboration with Merck KGaA now includes a complementary focus on translational programs as well as companion diagnostics.
C4XD Launches Precision Medicine Platform
A U.K. drug discovery company has launched the precision medicine platform PatientSeek, after it was able to identify a subgroup of patient responders in a failed Parkinson’s clinical trial.
Nucleai, Propath Partnership Paves Way for Spatial Oncology Biomarkers
Nucleai and Propath UK have announced a partnership to develop and validate an immunofluorescence assay focused on 30 immuno-oncology protein targets.
